Discontinued — last reported Q2 '25
Current Assets
Finished goods
Alnylam Pharmaceuticals Finished goods increased by 20.5% to $38.98M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 18.3%, from $32.96M to $38.98M. Over 5 years (FY 2020 to FY 2025), Finished goods shows an upward trend with a 20.6% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ3 2017
Last reportedQ2 2025
Parent metricInventories
How to read this metric
An increase relative to sales may signal slowing demand or overproduction; a decrease may indicate strong sales or supply chain constraints.
Detailed definition
This represents the value of inventory that has completed the manufacturing process and is ready for sale to customers....
Peer comparison
Standard inventory metric for all manufacturing and retail companies.
Metric ID:
inv_finished_goodsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $16.45M | $12.67M | $7.01M | $10.43M | $13.19M | $21.48M | $25.61M | $29.53M | $28.51M | $27.66M | $25.12M | $24.82M | $27.86M | $23.13M | $26.43M | $32.96M | $33.75M | $38.85M | $32.34M | $38.98M |
| QoQ Change | — | -23.0% | -44.7% | +48.9% | +26.5% | +62.8% | +19.2% | +15.3% | -3.5% | -3.0% | -9.2% | -1.2% | +12.2% | -17.0% | +14.3% | +24.7% | +2.4% | +15.1% | -16.8% | +20.5% |
| YoY Change | — | — | — | — | -19.8% | +69.6% | +265.5% | +183.2% | +116.1% | +28.7% | -1.9% | -16.0% | -2.3% | -16.4% | +5.2% | +32.8% | +21.2% | +68.0% | +22.3% | +18.3% |
| % of Inventories | 19.5% | 12.9% | 8.1% | 13.3% | 14.8% | 18.6% | 19.9% | 22.4% | 28.4% | 28.9% | 28.2% | 26.4% | 33.2% | 30.4% | 33.7% | 50.3% | 47.1% | 51.5% | 39.1% | 46.4% |
| Share Change | — | -6.6pp | -4.8pp | +5.2pp | +1.5pp | +3.8pp | +1.3pp | +2.5pp | +6.0pp | +0.5pp | -0.7pp | -1.8pp | +6.8pp | -2.7pp | +3.2pp | +16.6pp | -3.2pp | +4.5pp | -12.4pp | +7.3pp |
Range$7.01M – $38.98M
CAGR+19.9%
Avg YoY Growth+48.4%
Median YoY Growth+21.7%
Finished goods at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's finished goods?
- Alnylam Pharmaceuticals (ALNY) reported finished goods of $38.98M in Q1 2026.
- How has Alnylam Pharmaceuticals's finished goods changed year-over-year?
- Alnylam Pharmaceuticals's finished goods increased by 18.3% year-over-year, from $32.96M to $38.98M.
- What is the long-term trend for Alnylam Pharmaceuticals's finished goods?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's finished goods has grown at a 20.6% compound annual growth rate (CAGR), from $12.69M to $32.34M.
- What does finished goods mean?
- The value of completed products ready for sale.